Edition:
India

Endologix Inc (ELGX.OQ)

ELGX.OQ on NASDAQ Stock Exchange Global Select Market

5.20USD
2:29am IST
Change (% chg)

$-0.11 (-2.07%)
Prev Close
$5.31
Open
$5.30
Day's High
$5.50
Day's Low
$5.19
Volume
135,413
Avg. Vol
176,274
52-wk High
$7.66
52-wk Low
$4.08

Chart for

About

Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular... (more)

Overall

Beta: 0.67
Market Cap(Mil.): $478.08
Shares Outstanding(Mil.): 83.43
Dividend: --
Yield (%): --

Financials

BRIEF-Endologix Q3 loss per share $0.17

* Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

08 Nov 2017

BRIEF-Endologix appoints John Onopchenko as chief operating officer

* Endologix appoints John Onopchenko as chief operating officer Source text for Eikon: Further company coverage:

19 Oct 2017

BRIEF-Endologix says operations not materially affected by Santa Rosa fires‍​

* Comments on impact of the Santa Rosa fires impact on co's facility ‍​

12 Oct 2017

BRIEF-ENDOLOGIX GETS FDA NOD TO BEGIN CONFIRMATORY CLINICAL STUDY ON ITS NELLIX EVAS SYSTEM

* ENDOLOGIX RECEIVES IDE APPROVAL FOR THE EVAS2 CONFIRMATORY CLINICAL STUDY TO EVALUATE THE NELLIX® ENDOVASCULAR ANEURYSM SEALING SYSTEM

06 Oct 2017

BRIEF-Endologix announces CE Mark approval for Nellix Endovascular Aneurysm Sealing System

* Endologix announces CE Mark approval for the Nellix Endovascular Aneurysm Sealing System with the refined indications for use

21 Sep 2017

BRIEF-Endologix announces collaboration agreements with Japan Lifeline

* Endologix announces collaboration agreements with Japan Lifeline for the development and commercialization of thoracic endovascular systems in Japan

11 Sep 2017

BRIEF-Endologix Q2 loss per share $0.20

* Q2 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S

03 Aug 2017

Competitors

Earnings vs. Estimates